摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-羟基嘧啶-5-硼酸频哪酯 | 1073354-84-3

中文名称
2-羟基嘧啶-5-硼酸频哪酯
中文别名
5-(4,4,5,5-四甲基-1,3,2-二氧硼烷)-2(1H)-嘧啶酮
英文名称
2-hydroxypyrimidine-5-boronic acid pinacol ester
英文别名
5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-ol;5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrimidin-2-one
2-羟基嘧啶-5-硼酸频哪酯化学式
CAS
1073354-84-3
化学式
C10H15BN2O3
mdl
MFCD09037497
分子量
222.052
InChiKey
JRCSRFGCQSLWNZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    201-204°C
  • 密度:
    1.17±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.16
  • 重原子数:
    16
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.6
  • 拓扑面积:
    59.9
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2934999090

SDS

SDS:3f5fb0b05a352633af829e5728436fda
查看
Material Safety Data Sheet

Section 1. Identification of the substance
2-Hydroxypyrimidine-5-boronic acid pinacol ester
Product Name:
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

Section 3. Composition/information on ingredients.
2-Hydroxypyrimidine-5-boronic acid pinacol ester
Ingredient name:
CAS number: 1073354-84-3

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C10H15BN2O3
Molecular weight: 222.0

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    描述:
    4-(((trifluoromethyl)sulfonyl)oxy)-2H-thiochromen-7-yl pivalate 、 2-羟基嘧啶-5-硼酸频哪酯1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物caesium carbonate 作用下, 以 1,4-二氧六环 为溶剂, 反应 1.0h, 以15%的产率得到4-(2-hydroxypyrimidin-5-yl)-2H-thiochromen-7-yl pivalate
    参考文献:
    名称:
    NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF
    摘要:
    本公开涉及新型取代的N-(3-氟丙基)吡咯烷化合物,其化学式为(I-A),其中R1和R2分别独立代表一个氢原子或一个氘原子;A代表一个氧原子或氮原子;SERM-F代表一个选择性的雌激素受体调节剂片段,该片段包含一个与相邻“A”基团连接的芳基或杂芳基团。本公开还涉及化合物(I-A)的制备以及作为雌激素受体的抑制剂和降解剂的药物用途。
    公开号:
    US20200361918A1
点击查看最新优质反应信息

文献信息

  • [EN] NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF<br/>[FR] NOUVEAUX COMPOSÉS N-(3-FLUOROPROPYL)-PYRROLIDINE SUBSTITUÉS, LEURS PROCÉDÉS DE PRÉPARATION ET LEURS UTILISATIONS THÉRAPEUTIQUES
    申请人:SANOFI SA
    公开号:WO2018091153A1
    公开(公告)日:2018-05-24
    The present invention relates to novel substituted N-(3-fluoropropyl)-pyrrolidine compounds of formula (l-A): wherein R1 and R2 represent independently a hydrogen atom or a deuterium atom; A represents an oxygen or nitrogen atom; and SERM-F represents a selective estrogen receptor modulator fragment comprising an aryl or heteroaryl group linked to the adjacent "A" group. The invention also relates to the preparation and to the therapeutic uses of the compounds of formula (l-A) as inhibitors and degraders of estrogen receptors.
    本发明涉及新型的取代的N-(3-丙基)吡咯烷化合物,其化学式为(l-A):其中R1和R2分别独立代表一个氢原子或一个原子;A代表一个氧原子或氮原子;SERM-F代表一个选择性雌激素受体调节剂片段,该片段包含与邻近的“A”基团相连的芳基或杂芳基。本发明还涉及化合物(l-A)的制备方法以及作为雌激素受体的抑制剂和降解剂的医疗用途。
  • [EN] NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USEFUL FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES, KIDNEY DISEASE AND DIABETES<br/>[FR] AGONISTES DU RÉCEPTEUR A DU PEPTIDE NATRIURÉTIQUE UTILES POUR LE TRAITEMENT DE MALADIES CARDIOMÉTABOLIQUES, D'UNE MALADIE RÉNALE ET DU DIABÈTE
    申请人:MERCK SHARP & DOHME
    公开号:WO2020236688A1
    公开(公告)日:2020-11-26
    The present invention relates to Compounds of Formula I: I and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treatment of cardiometabolic diseases including high blood pressure, heart failure, kidney disease, and diabetes in a subject.
    本发明涉及公式I的化合物:I及其药用可接受的盐或前药。本发明还涉及包含至少一种公式I化合物的组合物,以及使用公式I化合物治疗心脏代谢疾病,包括高血压、心力衰竭、肾脏疾病和糖尿病的方法。
查看更多